Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Accounts Payables (2018 - 2025)

10x Genomics (TXG) has disclosed Accounts Payables for 8 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 1.36% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Dec 2025, down 1.36% year-over-year, with the annual reading at $12.7 million for FY2025, 1.36% down from the prior year.
  • Accounts Payables hit $12.7 million in Q4 2025 for 10x Genomics, down from $18.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $29.3 million in Q1 2023 to a low of $10.1 million in Q1 2025.
  • Historically, Accounts Payables has averaged $19.0 million across 5 years, with a median of $18.5 million in 2023.
  • Biggest five-year swings in Accounts Payables: soared 268.46% in 2021 and later crashed 50.2% in 2025.
  • Year by year, Accounts Payables stood at $17.4 million in 2021, then rose by 24.48% to $21.6 million in 2022, then decreased by 27.14% to $15.7 million in 2023, then dropped by 17.98% to $12.9 million in 2024, then fell by 1.36% to $12.7 million in 2025.
  • Business Quant data shows Accounts Payables for TXG at $12.7 million in Q4 2025, $18.1 million in Q3 2025, and $15.9 million in Q2 2025.